News
MOLN
3.800
-0.26%
-0.010
Weekly Report: what happened at MOLN last week (0615-0619)?
Weekly Report · 2d ago
Weekly Report: what happened at MOLN last week (0608-0612)?
Weekly Report · 06/15 09:59
Weekly Report: what happened at MOLN last week (0601-0605)?
Weekly Report · 06/08 09:56
Analysts Offer Insights on Healthcare Companies: Disc Medicine (IRON), Molecular Partners (MOLN) and Park Dental Partners, Inc. (PARK)
TipRanks · 06/05 03:40
Molecular Partners Starts Dosing DLL3 Radio-DARPin MP0712, Highlights Program at ASCO and SNMMI 2026
TipRanks · 06/01 11:59
Molecular Partners starts Phase 1/2a study of DLL3-targeting Radio-DARPin MP0712 in SCLC and neuroendocrine cancers
PUBT · 06/01 11:19
Weekly Report: what happened at MOLN last week (0525-0529)?
Weekly Report · 06/01 09:59
Molecular Partners to hold trial-in-progress presentations on Phase 1/2a study
TipRanks · 05/31 20:30
Molecular Partners starts Phase 1/2a trial of DLL3-targeting radiotherapy MP0712 in SCLC, neuroendocrine tumors
PUBT · 05/30 12:00
Molecular Partners Holds Presentations at ASCO and SNMMI 2026 on DLL3-Targeting Radio-DARPin MP0712, Now Dosing Patients in Phase 1
Barchart · 05/30 07:00
Molecular Partners to present at TD Cowen Oncology Innovation Summit fireside chat
PUBT · 05/26 20:00
Weekly Report: what happened at MOLN last week (0518-0522)?
Weekly Report · 05/25 10:01
Weekly Report: what happened at MOLN last week (0511-0515)?
Weekly Report · 05/18 10:01
Analysts Are Bullish on Top Healthcare Stocks: Molecular Partners (MOLN), Enliven Therapeutics (ELVN)
TipRanks · 05/16 14:40
Molecular Partners: Buy Rating Reaffirmed on Pipeline Progress and Cash Runway, $12 Price Target Unchanged
TipRanks · 05/12 23:15
Molecular Partners GAAP EPS of -$0.67 misses by $0.25
Seeking Alpha · 05/12 20:57
Molecular Partners Advances Radio-DARPin and Immuno-Oncology Pipeline on Solid Financial Footing in Q1 2026
TipRanks · 05/12 20:35
Molecular Partners Q1 FY26 net loss narrows to CHF 13.14 million
PUBT · 05/12 20:12
Molecular Partners Q1 EPS $(0.45) Misses $(0.38) Estimate
Benzinga · 05/12 20:04
Molecular Partners starts Phase 1/2a trial of DLL3-targeting radiotherapy MP0712
PUBT · 05/12 20:00
More
Webull provides a variety of real-time MOLN stock news. You can receive the latest news about MOLECULAR PARTNERS AG through multiple platforms. This information may help you make smarter investment decisions.
About MOLN
Molecular Partners AG is a Switzerland-based company engaged in the pharmaceuticals industry. As a biopharmaceutical company, it is active in the research and development of proteins like DARPins (Designed Ankyrin Repeat Proteins), a new class of small proteins used for the development of medicine against diseases like cancer and sight-threating diseases, among others. The Company’s pipeline is structured mainly through three areas: Ophthalmology, including the creation of therapies for renital diseases like wet age-related macular degeration (wet AMD) and diabetic macular edema (DME); Oncology, containing the development of DARPins against cancer, among others; and Immunology and other Indications, entailing DARPins against several targets important for the treatment of inflammatory and auto-immune diseases.